ESTRO 2022 - Abstract Book

S1129

Abstract book

ESTRO 2022

Conclusion As radiation oncologists, paying attention to toxicities related to oncological treatments is essential. Leaving taboos behind, it must be mandatory to ask for manifestations associated to cancer treatment-induced GSM in terms of vaginal dryness and sexual problems, specially in our young female cancer patients, and to offer them all the means available not only to improve but to prevent these symptons.

PO-1333 Hypofractionated Radiochemotherapy In Cervical Cancer: A Preliminar Experience

B. SANTO 1 , D. Russo 1 , M.C. Barba 1 , E. Cavalera 1 , E. Ciurlia 2 , P. De Franco 1 , G. Di Paola 1 , A. Leone 3 , A. Papaleo 1 , D. Musio 1

1 Vito Fazzi Hospital, Radiation Oncology, LECCE, Italy; 2 VCito Fazzi Hospital, Radiation Oncology, LECCE, Italy; 3 Viton Fazzi Hospital , Radiation Oncology, LECCE, Italy Purpose or Objective To evaluate feasibility and tolerability of hypofractionated external beam radiation therapy (EBRT) schedule with concurrent chemotherapy (weekly cisplatin 40mg/m2) in high volume and node positive cervical cancer (CC). Materials and Methods From March 2018 to July 2020, 15 consecutive patients, median age 59 (47-80) with locally advanced (IIB-IVa) high volume CC received exclusive chemoradiation. Hypofractionated EBRT was delivered using VMAT and a simoultaneous integrated boost. EBRT schedule was 66.08 Gy to primary, 59.92 Gy to positive nodes, 54.4 Gy to negative pelvic nodes and 50.4 Gy to lomboaortic nodes, when required, in 28 daily fractions. Pelvic RM was performed during the last week of EBRT to evaluate tumor response. Four patients received image guided brachytherapy boost (BRTb) (14 Gy in 2 weekly fractions), in 3 patients BRTb was technically not feasible, 2 patients were unfit to continue treatment, in 4 elderly patients BRTb was not planned. In 2 non responders patients, systemic therapy followed chemoradiation. Cone beam CT was acquired daily. Acute and late toxicity were registered using RTOG scales. Results Median follow-up is 18.7 months (0.33-38). The oldest patient of the series (80 years) died early for a cardiovascular event. Other 3 patients died after 17, 45 and 50 months respectively. Eleven patients are alive, 10 without evident disease and